SAN DIEGO, Dec. 12, 2017 /PRNewswire/ -- Trovagene, Inc.
(NASDAQ: TROV), a precision medicine biotechnology company,
today announced that its proprietary NextCollect™ urine collection
and DNA preservation kit is now available, for research use only,
to clinical research laboratories and pharmaceutical
customers. NextCollect™ is being offered to both existing
contracted clients and to new customers through an online ordering
web distribution portal. NextCollect™ enables high-volume,
non-invasive urine sample collection and isolation of DNA, and has
the potential to expand the utility of nucleic acid testing from
urine, including oncology, virology and infectious disease.
NextCollect™ accommodates up to 250 mL of volume in its urine
collection cup with a built-in delivery of a preservative fluid in
the collection cup lid to maximize the amount of cfDNA collected in
each urine sample, while minimizing total DNA degradation during
transport and storage. NextCollect™ is designed for
high-throughput lab processing with the ability to fit directly
into standard centrifuge systems for initial specimen DNA
separation requirements.
"We are pleased with the initial interest that we have received
on our NextCollect™ Kit," said Bill
Welch, Chief Executive Officer of Trovagene. "We look
forward to making NextCollect™ broadly available to academic
researchers, clinical research institutions and pharmaceutical
companies to support the demand for extracting DNA from urine for
many nucleic acid testing applications."
Trovagene plans to make its DNA Isolation Buffer Kits available
in early 2018 to complement the NextCollect™ collection
applications. These kits support the isolation of pre- and
post-renal cell free DNA and RNA, utilizing the methods developed
with the Trovera® ctDNA tests and can enable research laboratories
to extract significantly more DNA than currently available
methods.
About NextCollect™
NextCollect™ is a first of its kind proprietary high volume
urine specimen collection and stabilization kit. Formulated
DNA preservative solution is integrated into the NextCollect™
reservoir cap, and dispensed when the cap is secured to the
NextCollect™ cup. When added to the urine specimen,
NextCollect™ preserves DNA during transport for up to 2 weeks at
room temperature. NextCollect™ is designed to collect a higher
volume of urine specimen, containing more DNA available for testing
methods. NextCollect™ urine extracted DNA can be used for a
range of applications across oncology, urology, virology and
infectious disease. NextCollect™ is intended for Research Use Only
(RUO) and not for use in diagnostic procedures.
About Trovagene, Inc.
Trovagene is a precision medicine biotechnology company
developing oncology therapeutics for improved cancer care by
leveraging its proprietary Precision Cancer Monitoring® (PCM)
technology in tumor genomics. Trovagene has broad
intellectual property and proprietary technology to measure
circulating tumor DNA (ctDNA) in urine and blood to identify and
quantify potentially clinically-actionable markers for predicting
response to cancer therapies. Trovagene offers its PCM
technology at its CLIA/CAP – accredited laboratory and plans to
continue to vertically integrate its PCM technology with precision
cancer therapeutics. For more information, please visit
https://www.trovagene.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of words
such as "anticipate," "believe," "forecast," "estimated" and
"intend" or other similar terms or expressions that concern
Trovagene's expectations, strategy, plans or intentions. These
forward-looking statements are based on Trovagene's current
expectations and actual results could differ materially.
There are a number of factors that could cause actual events
to differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
our need for additional financing; our ability to continue as a
going concern; uncertainties of government or third party payer
reimbursement; dependence on key personnel; limited experience in
marketing and sales; substantial competition; uncertainties of
patent protection and litigation; dependence upon third parties;
our ability to develop tests, kits and systems and the success of
those products; regulatory, financial and business risks related to
our international expansion and risks related to failure to obtain
FDA clearances or approvals and noncompliance with FDA regulations.
There are no guarantees that any of our technology or
products will be utilized or prove to be commercially successful,
or that Trovagene's strategy to design its liquid biopsy tests to
report on clinically actionable cancer genes will ultimately be
successful or result in better reimbursement outcomes.
Investors should read the risk factors set forth in Trovagene's
Form 10-K for the year ended December 31, 2016, and other
periodic reports filed with the Securities and Exchange
Commission. While the list of factors presented here is
considered representative, no such list should be considered to be
a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles
to the realization of forward-looking statements.
Forward-looking statements included herein are made as of the
date hereof, and Trovagene does not undertake any obligation to
update publicly such statements to reflect subsequent events or
circumstances.
Trovagene Contact:
Vicki
Kelemen
VP, Corporate Communications
858-952-7652
vkelemen@trovagene.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/trovagene-announces-the-launch-of-nextcollect-urine-collection-and-dna-preservation-kit-to-research-laboratories-and-pharmaceutical-customers-300569896.html
SOURCE Trovagene, Inc.